Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Purinergic Signal ; 17(3): 481-492, 2021 09.
Article in English | MEDLINE | ID: mdl-34282551

ABSTRACT

Extracellular nucleotides act as danger signals that orchestrate inflammation by purinergic receptor activation. The expression pattern of different purinergic receptors may correlate with a pro- or anti-inflammatory phenotype. Macrophages function as pro-inflammatory M1 macrophages (M1) or anti-inflammatory M2 macrophages (M2). The present study found that murine bone marrow-derived macrophages express a unique purinergic receptor profile during in vitro polarization. As assessed by real-time polymerase chain reaction (PCR), Gαs-coupled P1 receptors A2A and A2B are upregulated in M1 and M2 compared to M0, but A2A 15 times higher in M1. The ionotropic P2 receptor P2X5 is selectively upregulated in M1- and M2-polarized macrophages. P2X7 is temporarily expressed in M1 macrophages. Metabotropic P2Y receptors showed a distinct expression profile in M1 and M2-polarized macrophages: Gαq coupled P2Y1 and P2Y6 are exclusively upregulated in M2, whereas Gαi P2Y13 and P2Y14 are overexpressed in M1. This consequently leads to functional differences between M1 and M2 in response to adenosine di-phosphate stimulation (ADP): In contrast to M1, M2 showed increased cytoplasmatic calcium after ADP stimulation. In the present study we show that bone marrow-derived macrophages express a unique repertoire of purinergic receptors. We show for the first time that the repertoire of purinergic receptors is highly flexible and quickly adapts upon pro- and anti-inflammatory macrophage differentiation with functional consequences to nucleotide stimulation.


Subject(s)
Inflammation Mediators/metabolism , Macrophages/metabolism , Receptors, Purinergic/biosynthesis , Transcriptome/physiology , Animals , Cell Polarity/physiology , Cells, Cultured , Mice , Receptors, Purinergic/genetics
2.
Sci Rep ; 10(1): 8423, 2020 05 21.
Article in English | MEDLINE | ID: mdl-32440003

ABSTRACT

Extracorporeal cardiopulmonary resuscitation (ECPR) is a last resort treatment option for refractory cardiac arrest performed in specialized centers. Following consensus recommendations, ECPR is mostly offered to younger patients with witnessed collapse but without return of spontaneous circulation (ROSC). We report findings from a large single-center registry with 252 all-comers who received ECPR from 2011-2019. It took a median of 52 min to establish stable circulation by ECPR. Eighty-five percent of 112 patients with out-of-hospital cardiac arrest (OHCA) underwent coronary angiography, revealing myocardial infarction (MI) type 1 with atherothrombotic vessel obstruction in 70 patients (63% of all OHCA patients, 74% of OHCA patients undergoing coronary angiography). Sixty-six percent of 140 patients with intra-hospital cardiac arrest (IHCA) underwent coronary angiography, which showed MI type 1 in 77 patients (55% of all IHCA patients, 83% of IHCA patients undergoing coronary angiography). These results suggest that MI type 1 is a frequent finding and - most likely - cause of cardiac arrest (CA) in patients without ROSC, especially in OHCA. Hospital survival rates were 30% and 29% in patients with OHCA and IHCA, respectively. According to these findings, rapid coronary angiography may be advisable in patients with OHCA receiving ECPR without obvious non-cardiac cause of arrest, irrespective of electrocardiogram analysis. Almost every third patient treated with ECPR survived to hospital discharge, supporting previous data suggesting that ECPR may be beneficial in CA without ROSC. In conclusion, interventional cardiology is of paramount importance for ECPR programs.


Subject(s)
Cardiopulmonary Resuscitation/methods , Coronary Angiography/methods , Extracorporeal Membrane Oxygenation/methods , Myocardial Infarction/epidemiology , Out-of-Hospital Cardiac Arrest/therapy , Acute Kidney Injury/complications , Female , Humans , Male , Middle Aged , Myocardial Infarction/mortality , Out-of-Hospital Cardiac Arrest/mortality , Out-of-Hospital Cardiac Arrest/pathology , Retrospective Studies , Survival Rate , Time Factors , Treatment Outcome
3.
Panminerva Med ; 57(4): 211-5, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26756697

ABSTRACT

The incidence of atrial fibrillation rises with advancing age. About 10% of patients over 80 years suffer from atrial fibrillation, but episodes are often not recognized. However, about 25% of cryptogenic strokes are caused by asymptomatic atrial fibrillation showing a significant risk of thromboembolism by this condition. New insertable cardiac monitors or wearable sensors offer the opportunity of continuous rhythm monitoring over wider time spans. Thereby, they enable detection of asymptomatic atrial fibrillation episodes. Several lines of evidence point towards an association between duration of asymptomatic episodes and thromboembolic risk. However, definite data on optimal risk stratification and therapy is missing in this collective. Currently, oral anticoagulation should be initiated according to the CHA2DS2VASc Score. Given the better safety profile of direct oral anticoagulants these substances should be preferred. In patients with high bleeding risk and asymptomatic atrial fibrillation, catheter-based left appendage occlusion may represent a valuable alternative to oral anticoagulation.


Subject(s)
Atrial Fibrillation/complications , Stroke/etiology , Humans , Incidence , Risk Factors , Stroke/therapy , Thrombolytic Therapy
4.
Thromb Haemost ; 112(2): 379-89, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24652469

ABSTRACT

The co-stimulatory immune molecule CD40L figures prominently in a variety of inflammatory conditions including arterial disease. Recently, we made the surprising finding that CD40L mediates atherogenesis independently of its classic receptor CD40 via a novel interaction with the leukocyte integrin Mac-1. Here, we hypothesised that selective blockade of the CD40L-Mac-1 interaction may also retard restenosis. We induced neointima formation in C57/BL6 mice by ligation of the left carotid artery. Mice were randomised to daily intraperitoneal injections of either cM7, a small peptide selectively inhibiting the CD40L-Mac-1 interaction, scM7, a scrambled control peptide, or saline for 28 days. Interestingly, cM7-treated mice developed neointima of similar size compared with mice receiving the control peptide or saline as assessed by computer-assisted analysis of histological cross sections. These data demonstrate that the CD40L-Mac-1 interaction is not required for the development of restenosis. In contrast, CD40-deficient mice subjected to carotid ligation in parallel, developed significantly reduced neointimal lesions compared with respective wild-type controls (2872 ± 843 µm² vs 35469 ± 11870 µm²). Flow cytometry in CD40-deficient mice revealed reduced formation of platelet-granulocyte and platelet-inflammatory monocyte- aggregates. In vitro, supernatants of CD40-deficient platelet-leukocyte aggregates attenuated proliferation and increased apoptosis of smooth muscle cells. Unlike in the setting of atherosclerosis, CD40L mediates neointima formation via its classic receptor CD40 rather than via its recently described novel interaction with Mac-1. Therefore, selective targeting of CD40L-Mac-1 binding does not appear to be a favorable strategy to fight restenosis.


Subject(s)
CD40 Antigens/metabolism , CD40 Ligand/antagonists & inhibitors , Carotid Arteries/drug effects , Carotid Stenosis/prevention & control , Macrophage-1 Antigen/drug effects , Neointima , Oligopeptides/pharmacology , Signal Transduction/drug effects , Animals , Apoptosis , CD40 Antigens/immunology , CD40 Ligand/genetics , CD40 Ligand/immunology , CD40 Ligand/metabolism , Carotid Arteries/immunology , Carotid Arteries/metabolism , Carotid Arteries/pathology , Carotid Stenosis/immunology , Carotid Stenosis/metabolism , Carotid Stenosis/pathology , Cells, Cultured , Disease Models, Animal , Leukocyte Rolling/drug effects , Macrophage-1 Antigen/immunology , Macrophage-1 Antigen/metabolism , Male , Mice, Inbred C57BL , Mice, Knockout , Muscle, Smooth, Vascular/metabolism , Muscle, Smooth, Vascular/pathology , Myocytes, Smooth Muscle/metabolism , Myocytes, Smooth Muscle/pathology , Platelet Activation/drug effects , Recurrence
5.
Hamostaseologie ; 34(1): 63-71, 2014.
Article in English | MEDLINE | ID: mdl-24343521

ABSTRACT

Throughout the last two decades inflammation has been recognized as the central mechanism underlying atherogenesis. A multitude of basic science work demonstrates the pivotal role of inflammatory processes during every step of atherosclerotic plaque formation: From initiation via propagation to complication. This review describes some of the key mechanisms involved with a particular focus on the diverse group of inflammatory cells and their subsets that distinctly contribute to atherogenic and anti-atherogenic phenomena. Furthermore, we summarize the controlling action of a tight network of co-stimulatory molecules and cytokines orchestrating the inflammatory and anti-inflammatory effector functions. Finally, the current status of clinical trials evaluating anti-inflammatory/immune-modulatory treatment strategies is summarized and an outlook for future therapeutic implications is provided.


Subject(s)
Atherosclerosis/immunology , Blood Vessels/immunology , Cytokines/immunology , Immunity, Innate/immunology , Immunologic Factors/immunology , Inflammation/immunology , Animals , Humans , Models, Cardiovascular , Models, Immunological
SELECTION OF CITATIONS
SEARCH DETAIL
...